ASCO Genitourinary Cancers Symposium

Videos

In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.

Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study

An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell carcinoma.

Toni Choueiri, MD, on How New Data Impact the Standard of Care for RCC

The CLEAR trial compared treatment with lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, on the Results of the Phase 3 CLEAR Trial for Advanced RCC

In the CLEAR study, investigators compared lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, on the Rationale Behind the Phase 3 CLEAR Trial for Advanced RCC

Articles

More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say.

Experts Attribute Higher Incidence of Metastatic Prostate Cancer in the US to Fewer PSA Screenings 

Findings from the phase 3 CONDOR trial support the use of the PSMA PET imaging agent 18F-DCFPyL as the FDA prepares to make a decision on a new drug application regarding its use.

PSMA PET Imaging Agent 18F-DCFPyL Enables Better Detection of Localized Metastatic Lesions

Investigational agent belzutifan plus cabozantinib was able to control tumor growth in most patients with advanced clear cell renal cell carcinoma in a phase 2 trial. 

Advanced Clear Cell RCC Has Favorable Response to Belzutifan/Cabozantinib, Early Findings Show

A phase 2 SWOG trial comparing multiple therapies versus sunitinib for papillary renal cell carcinoma revealed superior activity of cabozantinib in this setting. 

In Papillary RCC, Cabozantinib Bests Sunitinib for PFS

Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting. 



ASCO Genitourinary Cancers Symposium | Conference